Dynavax (DVAX) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Dynavax Revenue Highlights


Latest Revenue (Y)

$232.28M

Latest Revenue (Q)

$73.80M

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Dynavax Revenue by Period


Dynavax Revenue by Year

DateRevenueChange
2023-12-31$232.28M-67.86%
2022-12-31$722.68M64.45%
2021-12-31$439.44M844.00%
2020-12-31$46.55M32.18%
2019-12-31$35.22M329.60%
2018-12-31$8.20M2407.03%
2017-12-31$327.00K-97.04%
2016-12-31$11.04M172.67%
2015-12-31$4.05M-63.29%
2014-12-31$11.03M-1.95%
2013-12-31$11.25M15.82%
2012-12-31$9.71M-55.06%
2011-12-31$21.61M-9.75%
2010-12-31$23.95M-40.60%
2009-12-31$40.32M8.69%
2008-12-31$37.09M163.21%
2007-12-31$14.09M190.76%
2006-12-31$4.85M-66.93%
2005-12-31$14.65M-1.06%
2004-12-31$14.81M1693.22%
2003-12-31$826.00K-42.12%
2002-12-31$1.43M-39.51%
2001-12-31$2.36M100.00%
2000-12-31--

Dynavax generated $232.28M in revenue during NA 2023, up -67.86% compared to the previous quarter, and up 2833.42% compared to the same period a year ago.

Dynavax Revenue by Quarter

DateRevenueChange
2024-06-30$73.80M45.29%
2024-03-31$50.79M-8.64%
2023-12-31$55.60M-20.02%
2023-09-30$69.51M15.38%
2023-06-30$60.25M28.39%
2023-03-31$46.92M-74.57%
2022-12-31$184.49M9.99%
2022-09-30$167.74M-34.60%
2022-06-30$256.46M124.98%
2022-03-31$113.99M-41.56%
2021-12-31$195.07M80.17%
2021-09-30$108.27M105.19%
2021-06-30$52.77M-36.68%
2021-03-31$83.33M326.27%
2020-12-31$19.55M45.74%
2020-09-30$13.41M402.77%
2020-06-30$2.67M-75.57%
2020-03-31$10.92M3.30%
2019-12-31$10.57M-0.05%
2019-09-30$10.57M27.39%
2019-06-30$8.30M43.79%
2019-03-31$5.77M8.56%
2018-12-31$5.32M264.00%
2018-09-30$1.46M16.51%
2018-06-30$1.25M660.00%
2018-03-31$165.00K685.71%
2017-12-31$21.00K-60.38%
2017-09-30$53.00K-49.52%
2017-06-30$105.00K-29.05%
2017-03-31$148.00K-97.97%
2016-12-31$7.29M4401.23%
2016-09-30$162.00K-93.88%
2016-06-30$2.65M181.00%
2016-03-31$942.00K37.52%
2015-12-31$685.00K-42.34%
2015-09-30$1.19M-23.35%
2015-06-30$1.55M147.21%
2015-03-31$627.00K-72.46%
2014-12-31$2.28M3.08%
2014-09-30$2.21M-27.53%
2014-06-30$3.05M-12.86%
2014-03-31$3.50M22.87%
2013-12-31$2.85M-2.73%
2013-09-30$2.93M-13.71%
2013-06-30$3.39M62.69%
2013-03-31$2.08M15.45%
2012-12-31$1.81M-37.16%
2012-09-30$2.87M7.08%
2012-06-30$2.68M14.21%
2012-03-31$2.35M-79.43%
2011-12-31$11.43M873.34%
2011-09-30$1.17M-83.85%
2011-06-30$7.27M316.80%
2011-03-31$1.74M-1.25%
2010-12-31$1.77M-84.84%
2010-09-30$11.65M431.68%
2010-06-30$2.19M-73.74%
2010-03-31$8.34M281.18%
2009-12-31$2.19M-24.54%
2009-09-30$2.90M-81.74%
2009-06-30$15.88M-17.89%
2009-03-31$19.34M61.94%
2008-12-31$11.95M34.87%
2008-09-30$8.86M-11.23%
2008-06-30$9.98M58.03%
2008-03-31$6.31M-32.07%
2007-12-31$9.29M-

Dynavax generated $73.80M in revenue during Q2 2024, up 45.29% compared to the previous quarter, and up 157.26% compared to the same period a year ago.

Dynavax Revenue Breakdown


Dynavax Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 21Dec 20Dec 19Dec 18
Cp G1018-$38.21M$3.28M--
Other Revenue$18.99M$432.00K---
Product$213.29M$39.31M$34.64M$6.81M-
H E P L I S A V B$213.29M$800.00K---
Collaboration Revenue---$143.00K$1.39M

Dynavax's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (47.87%), H E P L I S A V B (47.87%), and Other Revenue (4.26%).

Quarterly Revenue by Product

Product/ServiceMar 24Dec 23Sep 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Dec 18Sep 18
Product$47.84M$150.98M$62.32M$82.89M$13.11M$13.28M$2.40M$10.51M$10.56M$10.16M$8.30M$5.63M$3.93M$1.46M------
H E P L I S A V B$47.84M$150.98M$62.32M$700.00K$11.51M---------------
Other Revenue$2.94M$11.79M$7.20M$263.00K$405.00K$-131.00K$417.00K-------------
Cp G1018---$87.04M$99.07M$126.37M$37.03M$1.16M$37.05M$74.58M$1.60M---------
Coalition For Epidemic Preparedness Innovations------$400.00K$68.00M$107.00M-----------
Collaboration Revenue-----------$100.00K$146.00K-------

Dynavax's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (48.51%), H E P L I S A V B (48.51%), and Other Revenue (2.99%).

Dynavax Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21
UNITED STATES$230.94M$8.77M$1.92M
Non-US$1.34M$588.65M$428.00K

Dynavax's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (99.42%), and Non-US (0.58%).

Quarterly Revenue by Country

CountryMar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
Non-US$1.29M---$147.24M$126.31M$223.58M$59.00K$74.00K---
UNITED STATES$49.50M$154.15M$69.51M$3.81M$3.47M$2.21M$3.88M$1.08M$1.61M$455.00K$23.91M$260.00K
Non Us----------$84.36M$39.08M

Dynavax's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (97.46%), and Non-US (2.54%).

Dynavax Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
NBIXNeurocrine Biosciences$1.89B$622.10M
ALKSAlkermes$1.66B$378.14M
LNTHLantheus$1.30B$394.09M
EBSEmergent BioSolutions$1.05B$254.70M
PCRXPacira BioSciences$674.98M$178.02M
AMPHAmphastar Pharmaceuticals$593.24M$182.39M
COLLCollegium Pharmaceutical$566.77M$144.92M
ANIPANI Pharmaceuticals$486.82M$138.04M
ITCIIntra-Cellular Therapies$462.18M$175.38M
IRWDIronwood Pharmaceuticals$442.74M$94.40M
EGRXEagle Pharmaceuticals$316.61M$64.65M
DVAXDynavax$232.28M$73.80M
DCPHDeciphera Pharmaceuticals$163.36M$45.00M
AQSTAquestive Therapeutics$50.58M$20.10M
DRRXDURECT$8.55M$1.83M

DVAX Revenue FAQ


Dynavax's yearly revenue for 2023 was $232.28M, representing a decrease of -67.86% compared to 2022. The company's yearly revenue for 2022 was $722.68M, representing an increase of 64.45% compared to 2021. DVAX's yearly revenue for 2021 was $439.44M, representing an increase of 844.00% compared to 2020.

Dynavax's quarterly revenue for Q2 2024 was $73.8M, a 45.29% increase from the previous quarter (Q1 2024), and a 22.48% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $50.79M, a -8.64% decrease from the previous quarter (Q4 2023), and a 8.24% increase year-over-year (Q1 2023). DVAX's quarterly revenue for Q4 2023 was $55.6M, a -20.02% decrease from the previous quarter (Q3 2023), and a -69.87% decrease year-over-year (Q4 2022).

Dynavax's revenue growth rate for the last 3 years (2021-2023) was -47.14%, and for the last 5 years (2019-2023) was 559.54%.

Dynavax's revenue streams in c 23 are Other Revenue, Product, and H E P L I S A V B. Other Revenue generated $18.99M in revenue, accounting 4.26% of the company's total revenue, up 4295.60% year-over-year. Product generated $213.3M in revenue, accounting 47.87% of the company's total revenue, up 442.64% year-over-year. H E P L I S A V B generated $213.3M in revenue, accounting 47.87% of the company's total revenue, up 26561.88% year-over-year.

For the fiscal year ending Dec 23, the largest source of revenue of Dynavax was Product. This segment made a revenue of $213.3M, representing 47.87% of the company's total revenue.